- Home
- HIHO vs KZIA Comparison
HIHO vs KZIA Comparison
Compare HIHO & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HIHO
- KZIA
- Stock Information
- Founded
- HIHO 1990
- KZIA 1994
- Country
- HIHO Hong Kong
- KZIA Australia
- Employees
- HIHO N/A
- KZIA N/A
- Industry
- HIHO Industrial Machinery/Components
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- HIHO Industrials
- KZIA Health Care
- Exchange
- HIHO Nasdaq
- KZIA Nasdaq
- Market Cap
- HIHO 7.6M
- KZIA 9.0M
- IPO Year
- HIHO 1996
- KZIA 1999
- Fundamental
- Price
- HIHO $1.68
- KZIA $7.94
- Analyst Decision
- HIHO
- KZIA Strong Buy
- Analyst Count
- HIHO 0
- KZIA 2
- Target Price
- HIHO N/A
- KZIA $14.00
- AVG Volume (30 Days)
- HIHO 200.7K
- KZIA 137.3K
- Earning Date
- HIHO 09-11-2025
- KZIA 11-14-2025
- Dividend Yield
- HIHO 7.02%
- KZIA N/A
- EPS Growth
- HIHO N/A
- KZIA N/A
- EPS
- HIHO 0.01
- KZIA N/A
- Revenue
- HIHO $7,080,000.00
- KZIA $1,549,158.00
- Revenue This Year
- HIHO N/A
- KZIA N/A
- Revenue Next Year
- HIHO N/A
- KZIA $49.25
- P/E Ratio
- HIHO $177.06
- KZIA N/A
- Revenue Growth
- HIHO 3.31
- KZIA 248983.08
- 52 Week Low
- HIHO $1.40
- KZIA $2.86
- 52 Week High
- HIHO $2.88
- KZIA $39.05
- Technical
- Relative Strength Index (RSI)
- HIHO 49.23
- KZIA 48.43
- Support Level
- HIHO $1.61
- KZIA $7.60
- Resistance Level
- HIHO $1.77
- KZIA $8.28
- Average True Range (ATR)
- HIHO 0.10
- KZIA 0.51
- MACD
- HIHO -0.00
- KZIA 0.03
- Stochastic Oscillator
- HIHO 25.00
- KZIA 30.88
About HIHO Highway Holdings Limited
Highway Holdings Ltd is a holding company. Along with its subsidiaries, it operates as a fully integrated manufacturer of high-quality metal, plastic, electric and electronic components, subassemblies, and finished products for OEMs and contract manufacturers. The manufacturing services offered by the group include metal stamping, screen printing, plastic injection molding, pad printing, and electronic assembly of printed circuit boards. Its reportable business segments are metal stamping and mechanical OEM operations, which derive maximum revenue, and electric OEM operations. Geographically, the group generates maximum revenue from Europe, and the rest from North America, Hong Kong and China, and other Asian countries.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.